CO4940427A1 - Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina - Google Patents

Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Info

Publication number
CO4940427A1
CO4940427A1 CO98014184A CO98014184A CO4940427A1 CO 4940427 A1 CO4940427 A1 CO 4940427A1 CO 98014184 A CO98014184 A CO 98014184A CO 98014184 A CO98014184 A CO 98014184A CO 4940427 A1 CO4940427 A1 CO 4940427A1
Authority
CO
Colombia
Prior art keywords
composition
prostaglandine
increasing
present
agent
Prior art date
Application number
CO98014184A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Yen Shau-Fong
Mary Sou
Flinn Peacock Regina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4940427A1 publication Critical patent/CO4940427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CO98014184A 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina CO4940427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CO4940427A1 true CO4940427A1 (es) 2000-07-24

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98014184A CO4940427A1 (es) 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Country Status (32)

Country Link
EP (1) EP0969846B2 (cg-RX-API-DMAC10.html)
JP (2) JP4920124B2 (cg-RX-API-DMAC10.html)
KR (1) KR100555818B1 (cg-RX-API-DMAC10.html)
CN (1) CN1236775C (cg-RX-API-DMAC10.html)
AR (2) AR002194A1 (cg-RX-API-DMAC10.html)
AT (1) ATE257385T1 (cg-RX-API-DMAC10.html)
AU (1) AU738781B2 (cg-RX-API-DMAC10.html)
BR (2) BRPI9816218B1 (cg-RX-API-DMAC10.html)
CA (1) CA2280089C (cg-RX-API-DMAC10.html)
CL (1) CL2009001870A1 (cg-RX-API-DMAC10.html)
CO (1) CO4940427A1 (cg-RX-API-DMAC10.html)
CY (1) CY2526B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ299833B6 (cg-RX-API-DMAC10.html)
DE (1) DE69820997T3 (cg-RX-API-DMAC10.html)
DK (1) DK0969846T4 (cg-RX-API-DMAC10.html)
EE (1) EE04091B1 (cg-RX-API-DMAC10.html)
ES (1) ES2214706T5 (cg-RX-API-DMAC10.html)
HU (1) HU228896B1 (cg-RX-API-DMAC10.html)
ID (1) ID22389A (cg-RX-API-DMAC10.html)
IL (1) IL131041A0 (cg-RX-API-DMAC10.html)
MY (1) MY122237A (cg-RX-API-DMAC10.html)
NO (1) NO327713B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ337322A (cg-RX-API-DMAC10.html)
PE (1) PE61899A1 (cg-RX-API-DMAC10.html)
PL (1) PL197509B1 (cg-RX-API-DMAC10.html)
PT (1) PT969846E (cg-RX-API-DMAC10.html)
RU (1) RU2197970C2 (cg-RX-API-DMAC10.html)
SI (1) SI0969846T2 (cg-RX-API-DMAC10.html)
TW (1) TW527187B (cg-RX-API-DMAC10.html)
UA (1) UA63938C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998041208A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA982188B (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
CN1933833B (zh) * 2004-03-18 2011-09-07 株式会社·R-技术上野 含有噻唑衍生物的含水组合物
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
KR20140083056A (ko) * 2006-03-17 2014-07-03 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PL2787968T3 (pl) 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
CA3136356A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
NO327713B1 (no) 2009-09-14
AU7035398A (en) 1998-10-12
PL197509B1 (pl) 2008-04-30
HU228896B1 (en) 2013-06-28
NO994481D0 (no) 1999-09-16
AR011192A1 (es) 2000-08-02
DK0969846T4 (da) 2010-12-20
ES2214706T5 (es) 2011-02-02
IL131041A0 (en) 2001-01-28
JP4920124B2 (ja) 2012-04-18
PT969846E (pt) 2004-05-31
DK0969846T3 (da) 2004-04-13
BRPI9816218B1 (pt) 2016-04-12
DE69820997T2 (de) 2004-12-09
EP0969846A1 (en) 2000-01-12
PE61899A1 (es) 1999-06-30
CN1236775C (zh) 2006-01-18
HUP0002194A2 (hu) 2000-12-28
JP2010043110A (ja) 2010-02-25
EP0969846B1 (en) 2004-01-07
ZA982188B (en) 1998-09-17
WO1998041208A1 (en) 1998-09-24
CZ325799A3 (cs) 2000-01-12
AU738781B2 (en) 2001-09-27
EE04091B1 (et) 2003-08-15
EE9900410A (et) 2000-04-17
CZ299833B6 (cs) 2008-12-10
ATE257385T1 (de) 2004-01-15
CA2280089C (en) 2009-03-03
CL2009001870A1 (es) 2010-01-22
ES2214706T3 (es) 2004-09-16
DE69820997D1 (de) 2004-02-12
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
MY122237A (en) 2006-04-29
SI0969846T1 (en) 2004-06-30
NO994481L (no) 1999-09-16
NZ337322A (en) 2001-05-25
JP2001515502A (ja) 2001-09-18
KR100555818B1 (ko) 2006-03-03
ID22389A (id) 1999-10-07
CN1249687A (zh) 2000-04-05
BR9808016A (pt) 2000-03-08
CY2526B1 (en) 2006-02-08
KR20000076330A (ko) 2000-12-26
EP0969846B2 (en) 2010-08-25
UA63938C2 (uk) 2004-02-16
TW527187B (en) 2003-04-11
HUP0002194A3 (en) 2012-08-28
HK1026841A1 (en) 2000-12-29
AR002194A1 (es) 1998-01-07
DE69820997T3 (de) 2011-10-06
PL335168A1 (en) 2000-04-10
RU2197970C2 (ru) 2003-02-10

Similar Documents

Publication Publication Date Title
AR011192A1 (es) Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma
ES2160631T3 (es) Composiciones de retinoides para aplicacion topica.
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
RU99121641A (ru) Композиции и способы, предназначенные для снижения глазной гипертензии
YU23599A (sh) Stabilizovani antihistaminski sirup
CO4750715A1 (es) Metodos para la limpieza e higiene de productos agricolas, composiciones y articulos de comercio
CO4700416A1 (es) Composiciones de pantalla solar y metodo para preparar las mismas
ES2161886T3 (es) Composiciones en barra de gel que comprenden gelificantes opticamente enriquecidos.
CO5050388A1 (es) Formulaciones de bromo oxidantes, estables, metodos de fabricacion de las mismas y metodos de uso para el control del microensuciamiento
ES2162614T1 (es) Composiciones formadoras de pelicula que comprenden almidones modificados e iota-carragaenina y metodo para producir capsulas blandas usando las mismas.
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
ATE174619T1 (de) Wäschenachbehandlungsmittel
ES8503944A1 (es) Procedimiento para la obtencion de una nueva composicion farmaceutica, casi neutra, de aplicacion topica
ES542041A0 (es) Procedimiento para la obtencion de una composicion detergente a base de un tenso activo no ionico eficaz a baja temperatura.
AR021949A1 (es) UNA COMPOSICIONES ToPICA ,SU USO, Y, UN MÉTODO COSMÉTICO QUE LA UTILIZA.
ES2184836T3 (es) Composiciones que contienen derivados de azol para aplicacion topica en la piel.
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
ES2195393T3 (es) Diesteres lipofilos de agentes quelantes.
ES2096648T3 (es) Composiciones para tratamiento contra los piojos.
KR970010742A (ko) 프로스타글란딘 유도체
DK0938584T3 (da) Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre
ES2137158T3 (es) N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
GB1472084A (en) Composition and method for sterilizing contact lenses